Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study.
HER2-positive
advanced salivary gland carcinoma
molecular profiling
pertuzumab
targeted therapy
trastuzumab
Journal
Annals of oncology : official journal of the European Society for Medical Oncology
ISSN: 1569-8041
Titre abrégé: Ann Oncol
Pays: England
ID NLM: 9007735
Informations de publication
Date de publication:
03 2020
03 2020
Historique:
received:
28
08
2019
revised:
08
11
2019
accepted:
28
11
2019
entrez:
19
2
2020
pubmed:
19
2
2020
medline:
7
1
2021
Statut:
ppublish
Résumé
Systemic therapy options for salivary cancers are limited. MyPathway (NCT02091141), a phase IIa study, evaluates targeted therapies in non-indicated tumor types with actionable molecular alterations. Here, we present the efficacy and safety results for a subgroup of MyPathway patients with advanced salivary gland cancer (SGC) matched to targeted therapies based on tumor molecular characteristics. MyPathway is an ongoing, multiple basket, open-label, non-randomized, multi-center study. Patients with advanced SGC received pertuzumab + trastuzumab (HER2 alteration), vismodegib (PTCH-1/SMO mutation), vemurafenib (BRAF V600 mutation), or atezolizumab [high tumor mutational burden (TMB)]. The primary endpoint is the objective response rate (ORR). As of January 15, 2018, 19 patients with SGC were enrolled and treated in MyPathway (15 with HER2 amplification and/or overexpression and one each with a HER2 mutation without amplification or overexpression, PTCH-1 mutation, BRAF mutation, and high TMB). In the 15 patients with HER2 amplification/overexpression (with or without mutations) who were treated with pertuzumab + trastuzumab, 9 had an objective response (1 complete response, 8 partial responses) for an ORR of 60% (9.2 months median response duration). The clinical benefit rate (defined by patients with objective responses or stable disease >4 months) was 67% (10/15), median progression-free survival (PFS) was 8.6 months, and median overall survival was 20.4 months. Stable disease was observed in the patient with a HER2 mutation (pertuzumab + trastuzumab, n = 1/1, PFS 11.0 months), and partial responses in patients with the PTCH-1 mutation (vismodegib, n = 1/1, PFS 14.3 months), BRAF mutation (vemurafenib, n = 1/1, PFS 18.5 months), and high TMB (atezolizumab, n = 1/1, PFS 5.5+ months). No unexpected toxicity occurred. Overall, 12 of 19 patients (63%) with advanced SGC, treated with chemotherapy-free regimens matched to specific molecular alterations, experienced an objective response. Data from MyPathway suggest that matched targeted therapy for SGC has promising efficacy, supporting molecular profiling in treatment determination.
Sections du résumé
BACKGROUND
Systemic therapy options for salivary cancers are limited. MyPathway (NCT02091141), a phase IIa study, evaluates targeted therapies in non-indicated tumor types with actionable molecular alterations. Here, we present the efficacy and safety results for a subgroup of MyPathway patients with advanced salivary gland cancer (SGC) matched to targeted therapies based on tumor molecular characteristics.
PATIENTS AND METHODS
MyPathway is an ongoing, multiple basket, open-label, non-randomized, multi-center study. Patients with advanced SGC received pertuzumab + trastuzumab (HER2 alteration), vismodegib (PTCH-1/SMO mutation), vemurafenib (BRAF V600 mutation), or atezolizumab [high tumor mutational burden (TMB)]. The primary endpoint is the objective response rate (ORR).
RESULTS
As of January 15, 2018, 19 patients with SGC were enrolled and treated in MyPathway (15 with HER2 amplification and/or overexpression and one each with a HER2 mutation without amplification or overexpression, PTCH-1 mutation, BRAF mutation, and high TMB). In the 15 patients with HER2 amplification/overexpression (with or without mutations) who were treated with pertuzumab + trastuzumab, 9 had an objective response (1 complete response, 8 partial responses) for an ORR of 60% (9.2 months median response duration). The clinical benefit rate (defined by patients with objective responses or stable disease >4 months) was 67% (10/15), median progression-free survival (PFS) was 8.6 months, and median overall survival was 20.4 months. Stable disease was observed in the patient with a HER2 mutation (pertuzumab + trastuzumab, n = 1/1, PFS 11.0 months), and partial responses in patients with the PTCH-1 mutation (vismodegib, n = 1/1, PFS 14.3 months), BRAF mutation (vemurafenib, n = 1/1, PFS 18.5 months), and high TMB (atezolizumab, n = 1/1, PFS 5.5+ months). No unexpected toxicity occurred.
CONCLUSIONS
Overall, 12 of 19 patients (63%) with advanced SGC, treated with chemotherapy-free regimens matched to specific molecular alterations, experienced an objective response. Data from MyPathway suggest that matched targeted therapy for SGC has promising efficacy, supporting molecular profiling in treatment determination.
Identifiants
pubmed: 32067683
pii: S0923-7534(19)41724-9
doi: 10.1016/j.annonc.2019.11.018
pmc: PMC9743163
mid: NIHMS1849778
pii:
doi:
Substances chimiques
Receptor, ErbB-2
EC 2.7.10.1
Trastuzumab
P188ANX8CK
Types de publication
Clinical Trial, Phase II
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
412-421Subventions
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2019 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Références
Mod Pathol. 2013 Aug;26(8):1086-100
pubmed: 23558567
Cancers Head Neck. 2016 Sep 1;1:11
pubmed: 31093341
Curr Opin Otolaryngol Head Neck Surg. 2018 Apr;26(2):142-151
pubmed: 29373327
Head Neck. 2014 Mar;36(3):E25-7
pubmed: 23852769
Clin Cancer Res. 2004 Feb 1;10(3):944-6
pubmed: 14871971
N Engl J Med. 2018 Feb 22;378(8):731-739
pubmed: 29466156
Ann Oncol. 2016 May;27(5):920-6
pubmed: 26884591
Clin Cancer Res. 2016 Sep 15;22(18):4623-33
pubmed: 27103403
J Clin Oncol. 2019 Jan 10;37(2):125-134
pubmed: 30452336
Oncotarget. 2015 Sep 22;6(28):25631-45
pubmed: 26247885
Ear Nose Throat J. 2017 Mar;96(3):E13-E16
pubmed: 28346649
Ann Surg Oncol. 2016 Dec;23(13):4376-4383
pubmed: 27338749
Ann Oncol. 2017 Oct 01;28(10):2539-2546
pubmed: 28961851
Ann Oncol. 2017 Apr 1;28(4):748-753
pubmed: 28327999
Head Neck. 2016 Apr;38 Suppl 1:E1838-47
pubmed: 26699379
Oncotarget. 2017 Jan 17;8(3):3946-3956
pubmed: 27992367
N Engl J Med. 2015 Aug 20;373(8):726-36
pubmed: 26287849
J Clin Oncol. 2018 Feb 20;36(6):536-542
pubmed: 29320312
Case Rep Oncol. 2018 May 02;11(2):252-257
pubmed: 29867432
Clin Cancer Res. 2016 Dec 15;22(24):6061-6068
pubmed: 27334835
J Clin Oncol. 2018 Aug 20;36(24):2532-2537
pubmed: 29989854
Nature. 2018 Feb 8;554(7691):189-194
pubmed: 29420467